In yesterday’s Wall Street session, Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares traded at $1.40, down -2.10% from the previous session.
DNA stock price is now -9.49% away from the 50-day moving average and -14.40% away from the 200-day moving average. The market capitalization of the company currently stands at $2.80B.
With the price target reduced from $3.50 to $2.50, Raymond James Downgraded its rating from Outperform to Mkt Perform for Ginkgo Bioworks Holdings Inc (NYSE: DNA).
In other news, Kelly Jason R, insider sold 100,000 shares of the company’s stock on Nov 30. The stock was sold for $135,300 at an average price of $1.35. Upon completion of the transaction, the insider now directly owns 4,694,680 shares in the company, valued at $6.57 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 30, 10% Owner Canton Barry sold 37,650 shares of the business’s stock. A total of $50,940 was realized by selling the stock at an average price of $1.35. This leaves the insider owning 12,487,494 shares of the company worth $17.48 million. Insiders disposed of 31,157,709 shares of company stock worth roughly $43.62 million over the past 1 year. A total of 34.05% of the company’s stock is owned by insiders.
Monday morning saw Ginkgo Bioworks Holdings Inc (NYSE: DNA) opened at $1.3800. During the past 12 months, Ginkgo Bioworks Holdings Inc has had a low of $1.12 and a high of $2.55. As of last week, the company has a debt-to-equity ratio of 0.32, a current ratio of 6.78, and a quick ratio of 6.78. The fifty day moving average price for DNA is $1.5468 and a two-hundred day moving average price translates $1.6356 for the stock.
The latest earnings results from Ginkgo Bioworks Holdings Inc (NYSE: DNA) was released for Sep, 2023. The net profit margin was -272.30% and return on equity was -63.83% for DNA. The company reported revenue of $55.43 million for the quarter, compared to $66.4 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -16.52 percent.
Ginkgo Bioworks Holdings Inc(DNA) Company Profile
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
